Tarsus Pharmaceuticals (TARS) Capital Expenditures Growth (3y) (2022 - 2026)
Tarsus Pharmaceuticals (TARS) Capital Expenditures Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 16.27% |
| 10 | Tarsus Pharmaceuticals | 2.61 Bn | 2.51 Bn | 152.66 Mn | 38.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.89% |
| Dec 31, 2025 | 290.86% |
| Jun 30, 2025 | 138.93% |
| Mar 31, 2025 | 54.17% |
| Dec 31, 2024 | 71.41% |
| Sep 30, 2024 | -36.87% |
| Jun 30, 2024 | 10.49% |
| Mar 31, 2024 | -48.24% |
| Dec 31, 2023 | -163.68% |
| Sep 30, 2023 | 69.80% |
| Jun 30, 2023 | -23.51% |
| Dec 31, 2022 | 43.67% |